Zentalis Pharmaceuticals
ZNTL
142 hedge funds and large institutions have $195M invested in Zentalis Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 57 increasing their positions, 31 reducing their positions, and 24 closing their positions.
84% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 31
38% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 24
4% more funds holding
Funds holding: 136 → 142 (+6)
3% more call options, than puts
Call options by funds: $229K | Put options by funds: $222K
9.41% less ownership
Funds ownership: 99.8% → 90.39% (-9.4%)
25% less capital invested
Capital invested by funds: $261M → $195M (-$66M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IHAM
Integral Health Asset Management
New York
|
+$3.44M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.63M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.62M |
| 4 |
AC
Almitas Capital
Santa Monica,
California
|
+$2.18M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.64M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$16M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$13.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.4M |
| 4 |
DC
Decheng Capital
Menlo Park,
California
|
-$2.52M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1.83M |
ZNTL Hedge Fund Activity: Q4 2024 in Review
142 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2024, worth a combined $195M — down 25% from $261M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ZNTL positions and 24 closed out — a net gain of 9 holders — while 57 added to existing stakes and 31 trimmed.
The largest buyer was Integral Health Asset Management, opening a new position worth an estimated $3.44M. The largest seller was Fidelity Investments, cutting an estimated $16M.
- 142 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2024, up from 136 in Q3 2024.
- Funds reported $195M of Zentalis Pharmaceuticals stock for Q4 2024, down 25% quarter-over-quarter.
- 33 funds opened new Zentalis Pharmaceuticals positions in Q4 2024 and 24 closed out, a net change of +9 holders.
- The largest Zentalis Pharmaceuticals buyer in Q4 2024 was Integral Health Asset Management, an estimated $3.44M added.
- The largest Zentalis Pharmaceuticals seller in Q4 2024 was Fidelity Investments, an estimated $16M sold.
Based on aggregated 13F filings for Q4 2024.